Pearl River Capital, LLC Crispr Therapeutics Ag Transaction History

Pearl River Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$51.17 - $68.18 $1.03 Million - $1.37 Million	20,132 Added 337.9%	26,090 $1.41 Million
Q1 2024 May 14, 2024	SELL	$60.67 - $89.12 $48,171 - $70,761	-794 Reduced 11.76%	5,958 $406,000
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $260,762 - $487,359	6,752 New	6,752 $422,000
Q4 2021 Feb 11, 2022	SELL	$70.09 - $111.29 $200,597 - $318,511	-2,862 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $315,392 - $448,303	2,862 New	2,862 $320,000
Q2 2019 Aug 12, 2019	SELL	$35.45 - $48.2 $249,851 - $339,713	-7,048 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$28.02 - $40.87 $197,484 - $288,051	7,048 New	7,048 $252,000

494

64.3M

1.68M

1.95M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.88B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.